CDC NEWS


powered by Surfing Waves


Latest News


Cold virus may set the stage for Long COVID


20 Sep 2023

At a Glance Prior infection with a common cold coronavirus may predispose some people to develop Long COVID. The findings identify a potential marker that could help identify people at high risk of developing Long COVID.


Genetic variant associated with absence of COVID-19 symptoms


09 Aug 2023

At least 20% of people infected with SARS-CoV-2, the virus that causes COVID-19, never showed symptoms. These asymptomatic infections could provide clues to how the virus can be quickly cleared from the body. Genetic factors may be involved. However, most studies of genetics and COVID-19 outcomes to date have focused on severe disease.


Delivering Extra Protection Against COVID-19


27 Jul 2023

What you need to know SARS-CoV-2, the virus that causes COVID-19, is covered in spike proteins. These spike proteins interact with a protein called angiotensin-converting enzyme 2 (ACE2) that sits on the surface of human cells. By attaching to ACE2, the virus can infect the human cells. Because ACE2 does not change, the part of the spike protein that interacts with ACE2 is unlikely to change or mutate. This makes the development of “decoy” ACE2 proteins — proteins that bind to SARS-CoV-2 before it can attach to human cells — a promising target for new treatments.


What Long COVID Looks Like in Children and Young Adults


22 May 2023

At least 15 million kids have been infected with SARS-CoV-2, the virus that causes COVID-19, but it is unclear how many of them have had or are living with long COVID. The ailment includes symptoms that linger after COVID-19 or symptoms that come back after an absence of weeks or months. A person might feel short of breath, lose their sense of smell, be unable to think clearly, be tired all the time, or have other maladies that can be traced back to COVID-19.


Rapid Progression of Dementia Following COVID-19


03 May 2023

What you need to know COVID-19 can cause long-term problems with thinking, concentrating, and remembering. This condition is commonly known as “brain fog.” Brain fog after COVID-19 has been studied mostly by observing previously healthy people. In a small study supported by the National Institute of Neurological Disorders and Stroke (NINDS), researchers examined the cognitive impact of COVID-19 on people with dementia. The researchers found that having COVID-19 rapidly accelerated the structural and functional brain deterioration of patients with dementia, regardless of the type of dementia being experienced.




Articles


Long-Term Dysfunction of Taste Papillae in SARS-CoV-2


06 Sep 2023

Abstract BACKGROUND We sought to determine whether ongoing taste disturbance in the post-acute sequelae of coronavirus disease 2019 is associated with the persistent virus in primary taste tissue. CONCLUSIONS Our data show a temporal association in patients between functional taste, taste papillae morphology, and the presence of SARS-CoV-2 and its associated immunological changes. (Funded by Intramural Research Program/National Institute on Aging/National Institute of Allergy and Infectious Diseases/National Institutes of Health; ClinicalTrials.gov numbers NCT03366168 and NCT04565067.)




Uninsured and Not Immune — Closing the Vaccine-Coverage Gap for Adults


20 Jul 2023

The U.S. Covid-19 vaccination strategy was simple: get safe and effective vaccines into arms as quickly as possible by making them free and accessible. This strategy worked: more than 670 million Covid-19 vaccine doses had been administered to more than 270 million Americans by the end of the national public health emergency.




Strategic Masking to Protect Patients from All Respiratory Viral Infections


06 Jul 2023

The end of the public health emergency in the United States is a richly symbolic milestone in the course of the SARSCoV-2 pandemic. During the height of the pandemic, the virus killed millions of people worldwide, upended lives, and radically altered health care. One of the most visible changes in health care was the introduction of universal masking, a measure designed to reduce SARS-CoV-2 transmission in health care facilities by applying source control and exposure protection to everyone in the facility. With the end of the public health emergency, however, many health care centers in the United States are now stopping universal masking and reverting to requiring masking in only limited circumstances (e.g., when health care workers are caring for patients with potentially contagious respiratory infections).




Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection


25 May 2023

Key Points Question What symptoms are differentially present in SARS-CoV-2–infected individuals 6 months or more after infection compared with uninfected individuals, and what symptom-based criteria can be used to identify postacute sequelae of SARS-CoV-2 infection (PASC) cases? Findings In this analysis of data from 9764 participants in the RECOVER adult cohort, a prospective longitudinal cohort study, 37 symptoms across multiple pathophysiological domains were identified as present more often in SARS-CoV-2–infected participants at 6 months or more after infection compared with uninfected participants. A preliminary rule for identifying PASC was derived based on a composite symptom score. Meaning A framework for identifying PASC cases based on symptoms is a first step to defining PASC as a new condition. These findings require iterative refinement that further incorporates clinical features to arrive at actionable definitions of PASC.




11 clinical trials that will shape medicine in 2023


23 Dec 2022

2022 has been a rollercoaster year for biopharma, as it has faced an industry-wide slowdown and late-stage clinical trial failures, as well as breakthroughs and regulatory approvals. COVID-19 has continued to disrupt nearly all aspects of clinical trial infrastructure, from patient recruitment to supply chains, but despite this, 2023 promises to bring many new readouts from different branches of medicine (Table 1). Nature Medicine asked 11 leading experts for their top clinical trials to watch in the coming year




Enroll for Free